Exo
Exo Imaging builds the Exo Iris handheld ultrasound device on proprietary pMUT chip technology, paired with FDA-cleared on-device AI applications (cardiac, lung, fluid management) and the Exo Works workflow platform, serving hospitals, EDs, medical schools, and individual clinicians.
- Company typePrivate
- Founded2015
- HeadquartersRedwood City, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Exo does
Exo Imaging, Inc. is a privately held medical device company founded in 2015 and headquartered in Santa Clara, California, that develops handheld point-of-care ultrasound (POCUS) systems and AI-enabled imaging software. The company's flagship product is the Exo Iris, a pocket-sized ultrasound device built on proprietary Piezoelectric Micromachined Ultrasonic Transducer (pMUT) chip technology that delivers phased, curved, and linear imaging from a single probe. The platform is augmented by SweepAI, an FDA-cleared on-device AI scanning assistant; Exo U, an AI coaching and microlearning application; and Exo Works, a vendor-neutral workflow solution for documentation, quality assurance, billing, and credentialing.
Exo monetizes through hardware sales of the Exo Iris device, subscription-based Exo Works software available in Connect and Enterprise tiers, and bundled AI applications covering cardiac, lung, fluid management, and population health diagnostics. The company employs a hybrid go-to-market motion combining direct enterprise sales to health systems, an e-commerce storefront for individual practitioners, and strategic distribution partnerships, most notably a May 2025 collaboration with Samsung Medison. Named customers include Wellstar MCG Health, Geisinger, Northwestern Medicine, Medical College of Georgia, and Highland Hospital, with use cases spanning hospitals, emergency departments, critical care, cardiology, medical schools, and primary and rural care settings. As of April 2025 Exo had secured 10 FDA 510(k) clearances for AI indications.
The company has raised more than $320 million in venture capital, including a $220 million Series C in July 2021 led by RA Capital Management with participation from BlackRock, Intel, Sony Innovation Fund, and other investors. In July 2022 Exo acquired Canadian AI ultrasound firm Medo to accelerate its AI capabilities, and in May 2025 the company entered a strategic partnership with Samsung Medison accompanied by a potential $100 million investment from Samsung Ventures.
Exo firmographics
Firmographics- Name
- Exo
- Legal name
- Exo Imaging, Inc.
- Website
- https://exo.inc
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Exo Imaging builds the Exo Iris handheld ultrasound device on proprietary pMUT chip technology, paired with FDA-cleared on-device AI applications (cardiac, lung, fluid management) and the Exo Works workflow platform, serving hospitals, EDs, medical schools, and individual clinicians.
- Ownership category
- akta.pro rank
Exo industry classification
Industry- Product category
- Point-of-Care Ultrasound Systems
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Ultrasound & Echography Systems (HLAHABAD)
- akta.pro secondary industry
- Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)
Keywords
Where Exo is headquartered
LocationHeadquarters
- HQ city
- Redwood City
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Exo business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Hardware Sales - Exo Iris Device: Sale of the Exo Iris handheld ultrasound device, a high-performance POCUS device priced at a fraction of traditional cart-based ultrasound systems. The device serves as the foundation of the company's medical imaging ecosystem.
- Software Subscriptions - Exo Works: Subscription-based POCUS workflow software providing documentation, QA, billing, and credentialing capabilities. Available in Enterprise and Connect tiers with per-user or institutional pricing.
- AI Application Licensing: FDA-cleared AI applications (cardiac, lung, fluid management, population health) integrated into the Exo Iris device and available as part of the platform. Revenue derived from device sales and potential per-feature licensing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Exo Iris handheld ultrasound device with integrated AI capabilities |
| Subscription | Annual | Exo Works Connect - streamlined POCUS workflow for clinical and educational programs |
| Subscription | Annual | Exo Works Enterprise - full-featured POCUS workflow with advanced customization |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels8 records
Exo product offering
Product offeringCore offering
Exo designs, manufactures, and sells a pocket-sized handheld ultrasound device (Exo Iris) powered by proprietary pMUT chip technology, bundled with FDA-cleared AI applications for cardiac, lung, fluid management, and population health diagnostics, and complemented by a cloud-based POCUS workflow software (Exo Works) for documentation, QA, billing, and credentialing. The company offers a complete medical imaging ecosystem targeting healthcare providers, health systems, and medical education institutions.
Product overview
Exo offers a unified medical imaging platform centered on its Exo Iris handheld ultrasound device, combined with a modular suite of AI-powered software solutions. The platform architecture consists of Exo Iris (the core hardware device featuring proprietary pMUT chip technology), augmented by four key software modules: SweepAI (real-time scanning guidance and auto-capture), Exo U (AI-powered education and coaching), and Exo Works (workflow management for documentation, QA, billing, and credentialing). The platform delivers FDA-cleared AI applications for cardiac, lung, fluid management, and population health diagnostics. Exo also acquired Medo in 2022 to enhance its AI capabilities. The company has raised over $320 million in total funding, with Samsung Medison announcing a strategic partnership in 2025.
Differentiator
Problem solved
Functional benefit
Brands
- Exo Iris: High-performance pocket-sized handheld ultrasound device with FDA-cleared AI applications for cardiac, lung, fluid management, and population health insights.
- Exo Works
- SweepAI
- Exo U
Products and services
- Exo Iris Pocket-sized, FDA-cleared handheld ultrasound device powered by proprietary pMUT chip technology. Provides high-performance whole-body ultrasound imaging with phased, curved, and linear capabilities in a smartphone-sized form factor, replacing cart-based systems for healthcare providers across emergency medicine, critical care, cardiology, and primary care settings.
- Exo Works Vendor-neutral POCUS workflow software solution that enables clinicians to document ultrasound exams in seconds, manage quality assurance from anywhere, automatically save to EMR and PACS, handle billing with integrated CPT codes, and track user proficiency and credentialing. Available in Connect (streamlined) and Enterprise (full-featured) tiers. Integrates with Epic, Cerner, PACS, VNA, and DICOM-enabled devices. HIPAA, HITRUST, SOC 2 Type II, ISO 27001, and ISO 27701 compliant.
- SweepAI FDA-cleared AI scanning technology that provides real-time feedback during ultrasound scanning, automatically identifying optimal imaging views, monitoring image quality, auto-capturing key views, and providing diagnostic insights without internet or cloud reliance. Functions as an autonomous scanning assistant that continuously evaluates and monitors ultrasound image quality.
- Exo U On-device AI education platform providing real-time ultrasound coaching, anatomical labeling, and microlearning videos (described as 'TikTok for POCUS'). Designed to help clinicians improve scanning skills through AI-guided probe motion and educational content.
Quantifiable outcome
- 203% ROI within 9 months for health systems implementing Exo Works
- +9 more outcomes
Companies that use Exo
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles3 records
Exo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration8 records
AI capability4 records
Feature9 records
Exo partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Samsung MedisoncoreStrategic collaboration announced May 27, 2025 for Exo's portable AI-powered ultrasound device. Samsung Medison is a Samsung subsidiary specializing in medical ultrasound and digital radiography systems. Dr. Omar Ishrak, former Intel CEO and Samsung Medison chairman, joined Exo's board as part of this collaboration. The partnership aims to enhance Exo's commercial expansion and leverage Samsung's global distribution network.
- MedocoreAcquired by Exo in July 2022. Canadian AI technology developer focused on simplifying ultrasound use through AI. Led by Dornoosh Zonoobi, Medo had developed two FDA-cleared products and deployed in four countries before acquisition.
- Wellstar MCG HealthcoreImplemented Exo Works workflow solution across emergency and internal medicine departments. Achieved 47% revenue capture increase and 203% ROI within 9 months. Medical College of Georgia also pilots Exo Works for student training.
Scale indicators19 records
Recent moves1 record
Expansion highlights6 records
Exo competitors and assessment
Company assessmentDirect peers
- Butterfly Network: Public handheld POCUS competitor using proprietary CMUT chip technology on a smartphone-connected platform with FDA-cleared AI. Closely comparable to Exo in target customers (emergency medicine, cardiology, primary care), chip-based architecture, and AI-augmented imaging strategy.
- GE HealthCare: Operates the Vscan Air handheld ultrasound line competing directly with Exo Iris in cardiology, emergency medicine, and primary care. GE HealthCare brings incumbent hospital relationships, global distribution, and a broad imaging portfolio that creates both direct competition and a potential partnership channel.
- Philips: Sells the Lumify handheld POCUS system, a smartphone-connected ultrasound probe targeting similar clinical settings and customer profiles as Exo Iris. Comparable through its handheld form factor, AI-enabled imaging features, and global hospital sales channel.
- Clarius Mobile Health: Vancouver-based handheld POCUS vendor offering wireless, AI-enabled ultrasound scanners for emergency medicine, critical care, and medical education. Highly comparable in product positioning, AI strategy, and target customer segments to Exo's Iris and Exo U offerings.
Broad incumbents
- Siemens Healthineers: Global medical imaging incumbent with a large ultrasound portfolio across cart-based and handheld systems, including ACUSON POCUS offerings. Comparable as a broader ultrasound player that overlaps with Exo in clinical use cases but does not focus exclusively on handheld POCUS.
- Fujifilm SonoSite: Established POCUS specialist with both handheld and cart-based ultrasound systems and a long-standing footprint in emergency medicine and anesthesia. Comparable through overlapping POCUS use cases and customer base, though SonoSite's product mix is broader than Exo's handheld focus.
- Canon Medical Systems: Major imaging equipment vendor offering ultrasound systems used in hospitals and specialty practices. Comparable as a broader medical imaging incumbent with overlap in clinical ultrasound applications, though Canon's primary focus is cart-based systems.
- Mindray: Chinese medical device manufacturer offering a broad range of ultrasound systems including handheld POCUS products, with growing U.S. and international presence. Comparable through handheld POCUS product overlap, particularly in price-sensitive segments.
Others
- Samsung Medison: Samsung's medical imaging subsidiary focused on ultrasound and digital radiography. Listed as a peer because of its May 2025 strategic partnership with Exo and overlapping ultrasound category, while also functioning as a potential channel and investor rather than a direct handheld POCUS competitor.
Emerging players
- EchoNous: Emerging handheld POCUS company focused on AI-enabled cardiac, lung, and abdominal assessment at the bedside. Comparable as a niche AI-ultrasound player targeting overlapping clinical use cases and customer segments, though with a narrower product footprint than Exo.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Exo social profiles
Digital presenceExo compliance and trust
Trust signalCompliance7 records
Exo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Exo leadership team
Management profileNumber of profiles
Profiles12 records
Exo subsidiaries and ownership
Company hierarchySubsidiaries1 record
Exo funding detail
Funding detailFunding overview
Funding rounds9 records
Investors27 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Exo M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Exo
What does Exo do?
Exo designs, manufactures, and sells a pocket-sized handheld ultrasound device (Exo Iris) powered by proprietary pMUT chip technology, bundled with FDA-cleared AI applications for cardiac, lung, fluid management, and population health diagnostics, and complemented by a cloud-based POCUS workflow software (Exo Works) for documentation, QA, billing, and credentialing. The company offers a complete medical imaging ecosystem targeting healthcare providers, health systems, and medical education institutions.
Is Exo a public or private company?
Exo is a private company. It is classified as venture growth investor backed and is currently operating.
When was Exo founded?
Exo was founded in 2015. It employs 1 to 10 people.
Where is Exo based?
Exo is headquartered in Redwood City, United States, in the North America region.
How does Exo make money?
Three revenue lines are on record. Hardware Sales - Exo Iris Device is the primary driver. The others are software Subscriptions - Exo Works and AI Application Licensing.
Who are Exo's main competitors?
Direct peers on record are Butterfly Network, GE HealthCare, Philips and Clarius Mobile Health. Broad incumbents are Siemens Healthineers, Fujifilm SonoSite, Canon Medical Systems and Mindray. Samsung Medison is listed as an others. EchoNous is listed as an emerging player.
Does Exo have an API?
No public API is recorded for Exo.
What industry is Exo in?
Exo's product category is Point-of-Care Ultrasound Systems. Its primary akta.pro industry code is HLAHABAD, Ultrasound & Echography Systems, with a secondary code of HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence). Its NAICS code is 334510 and its SIC code is 3845.